29.06  0 (0%)		02-23 16:00
Open: 29.17 High: 29.345 Volume: 0		Pre. Close: 29.06 Low: 29.02 Market Cap: 1,272(M)

Short term
Mid term
Targets	6-month :	34.24	1-year :	34.66
Resists	First :	29.32	Second :	29.68
Pivot price	29.21
Supports	First :	28.74	Second :	23.91
MAs	MA(5) :	29.05	MA(20) :	29.22
	MA(100) :	24.81	MA(250) :	24.06
MACD	MACD :	0.7	Signal :	1.1
%K %D	K(14,3) :	15.6	D(3) :	15.6
RSI	RSI(14): 69.2
52-week	High :	43.15	Low :	10.52

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CINC ] has closed above bottom band by 27.4%. Bollinger Bands are 93.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	29.09 - 29.23	29.23 - 29.35
Low:	28.72 - 28.88	28.88 - 29.03
Close:	28.81 - 29.07	29.07 - 29.29

CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Mon, 09 Jan 2023
AstraZeneca reaches deal to buy CinCor Pharma for up to $1.8B - Philadelphia Business Journal - The Business Journals

Mon, 09 Jan 2023
AstraZeneca To Acquire CinCor Pharma To Strengthen Cardiorenal Pipeline - Yahoo Finance

Mon, 09 Jan 2023
AstraZeneca boosts heart, kidney business with $1.8 bln CinCor deal - Reuters.com

Mon, 09 Jan 2023
CinCor Pharma Stock Surges on Deal to Be Acquired by AstraZeneca - Barron's

Mon, 09 Jan 2023
CinCor Pharma to be Acquired by AstraZeneca - Yahoo Finance

Fri, 04 Nov 2022
Correcting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate Update - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	44 (M)
Shares Float	18 (M)
Held by Insiders	12 (%)
Held by Institutions	94.1 (%)
Shares Short	339 (K)
Shares Short P.Month	2,170 (K)

EPS	-2.01
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	11.85
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-15.3 %
Return on Equity (ttm)	-27 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-64 (M)
Levered Free Cash Flow	-50 (M)

PE Ratio	-14.46
PEG Ratio	0
Price to Book value	2.45
Price to Sales	0
Price to Cash Flow	-19.79

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.